Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
- Inside ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive T-Cell Malignancies
- Demonstrating Non-Inferiority Of BFPCs Vs. Traditional Air Monitoring
- Pharmacogenomics In Oncology: A Pharmacokinetic Perspective
- Solving Vector Yield Challenges Starts Long Before Manufacturing
- The Missing Layer: Why CAR-T Needs AI As Its Connective Tissue
- Building A Self-Driving Lab For LNP Development
- Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors
- Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Recruiting & Retaining More Patients Per Site:
Through Home Trial Support (HTS) services, MRN is able to enhance the accessibility of clinical trials while reducing the emotional toll on their patients suffering from loss of mobility.
-
Solutions For CQA Analysis Of IVT mRNA-Based Biotherapeutics
Discover new innovative solutions for mRNA analysis, enhancing accuracy and efficiency in IVT mRNA workflows, including advanced technologies and methodologies to optimize your research and development processes.
-
Automation Of iPSC Culture, Passaging, And Expansion
Find out how iPSC-derived models enable researchers to generate diverse cell types and tissues as well as how automation reduces the labor-intensive culturing process with AI-powered decision-making.
-
A Bright Future For Eye Care: The Advanced Therapy Revolution Is Here
Groundbreaking cell and gene therapies are revolutionizing eye care. Discover how advanced treatments target root causes, offering unprecedented hope for conditions previously deemed untreatable.
-
How Ergonomics And Cleaning Ease Reduce Repetitive Stress Injuries And Contamination In Pharmaceutical Lab Workflows
The repetitive nature of routine laboratory procedures can put technicians and scientists at risk for repetitive strain injury. Routine activities often include reoccurrence of the same movements over and over, which can take a toll on hands, wrists and shoulders and ultimately can lead to serious damage. Choosing the right tools can make all the difference.
-
Implementing Raman Spectroscopy For Automated Monitoring Of A Cell Culture Bioprocess
Discover how Raman spectroscopy and parallel bioprocessing enable real-time cell culture monitoring, saving time and providing crucial data for process optimization in biopharmaceutical production.
-
AAV Capsid Analysis With Single Particle Mass Photometry
Accurate AAV capsid ratios are critical to gene therapy efficacy. See how mass photometry delivers faster, lower-cost E/F analysis with single-particle resolution.
-
Achieving High Cell Purity With The CTS DynaCellect Magnetic Separation System
Learn how closed-system automation, combined with expert technical guidance and protocol optimization, turned a persistent manufacturing bottleneck into a reliable, scalable process.
-
What the FDA Looks For In Global Development Programs Today
Mastering the complexities of multi-regional clinical trials requires aligning global data with evolving regulatory expectations to ensure treatment consistency and successful drug approval.
-
Building A Scalable Digital Foundation To Support CGT Manufacturing
Explore how digital systems strengthen CGT manufacturing by improving traceability and managing batch‑of‑one, as well as essential steps toward scalable, integrated operations.
NEWSLETTER ARCHIVE
- 07.31.26 -- Supply Chain Orchestration, Priorities For Smaller CGT Biotechs
- 07.30.26 -- Innovations To Support Scale And Efficiency In Your Process
- 07.30.26 -- Addressing The Particulate Challenge In Cell Therapy Products
- 07.29.26 -- Key Considerations for Combination Product Development
- 07.29.26 -- Full FDA Approval For TECELRA Is More Than A Regulatory Win For Solid Tumors
- Solving Vector Yield Challenges Starts Long Before Manufacturing
- Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors
- FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy
- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale
- In Vivo Gene Editing Is Moving From Promise To Proof
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections